Journal for ImmunoTherapy of Cancer

Title Publication Date Language Citations
Immunogenic cell death induced by a new photodynamic therapy based on photosens and photodithazine2019/12/01English169
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)2019/12/01English167
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma2015/06/16English164
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade2014/12/01English162
Monalizumab: inhibiting the novel immune checkpoint NKG2A2019/10/17English161
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy2017/05/16English159
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance2018/12/01English159
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances2020/02/01English159
Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?2019/03/28English157
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial2018/11/16English157
Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson2018/05/11English153
Soluble immune checkpoints in cancer: production, function and biological significance2018/11/27English152
The immune system in cancer metastasis: friend or foe?2017/10/17English151
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature2019/11/21English151
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease2018/05/14English149
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)2018/07/17English148
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?2016/08/16English148
Pembrolizumab2015/08/18English147
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma2015/05/19English145
Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma2014/05/13English145
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors2019/09/05English144
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study2016/03/15English143
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial2020/07/01English141
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study2018/10/22English139
Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape2019/08/22English139
Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of MICA/B and NKG2A targeting for cancer treatment2019/03/14English138
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study2018/12/01English134
Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers2016/03/15English134
Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results2015/04/21English134
Novel technologies and emerging biomarkers for personalized cancer immunotherapy2016/01/19English134